# Definium's LSD-based anxiety, depression drug scores another trial win

> **Open Intelligence Dossier** · First detected: 2026-09-15 18:00 UTC · Category: Business

## Executive Summary
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Definium's LSD-based anxiety, depression drug scores another trial win" is generating significant coverage in the Business category, with 4 articles from 4 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Fierce Biotech, Pharmaceutical Technology, New Scientist and Yahoo Finance. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Fierce Biotech | Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxOZ3hnZEpYUkhFRHM2Nzd6dmdFUEs5cjlldGF2VjFXeE9mVEx6dU5nZ2hLSVhWU3d2ZklPc25IcFBpelFUVnphVTlOZktPNXFWemVlMzJTQUtrSWlNQUwwVm9idExTaFVKTElkNTUyZVQzazgxQ2NXX21SVTd0UUtjUm9pTFItdTJSY2JoLWJYWFhXLWoxWFpzWUpZeG5lTEk?oc=5) |
| Pharmaceutical Technology | Definium tees up regulatory submission for psychedelic on Phase III hat trick | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxPOFNJd0UyS3VqUGJtMl9PUUl5ZWV6enJFUHFfdFZHRC0zM3d2TWJnWVhFckZFb3hsYjNlYk9WMnAzR1VWbE5xSnlheEo5Q0tyMmRoTEFzQ041S1YtNjEyOGwwRERabUFHUFAtejBRWmRyNEpGV1dZZUhXMFNTVzNJbVJYV0luT0oxZnVJRGF6V2F2Z3d0S3FRUTNEcU0?oc=5) |
| New Scientist | LSD could be approved for anxiety in the US in 2027 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxPYWdILXR4ZGFMNHJnMlQyOFhrMTlubFdTUjhqVzBiMW42eVNFcW85TW9FZWZpNW00SmhhVnlkWXZoWDFIaU1OcXZITi1IWW5qcDM3VFhoSVJocVp4UDZnUGtUYlhVVS1JbnNkcTN3SEd6QVZyd2pJbTRsXzhEckhrTjFnb0FqMU9BSHNOQUphRkM?oc=5) |
| Yahoo Finance | Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxPNTRBb28zczd4bjkxUlNPZ3RGWHR6VkhTSTZzS0ViN1J0bFdhc0kwZnlPY0s2bmdFT2FPTmw2bVBUT1lBZ3EzZk1zazRseFNxR05JWjhCdnQ3MWxsREtST3ZVSEdYTndLb3lpdWRCSmdmX21VN1U1bW1NakF0MHZid0RYMkJ1TVJibjJKRTdqS3NTb0k2V0p1eGNSLTc5RjFzTC1B?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-15/definium-s-lsd-based-anxiety-depression-drug-scores-another-trial-win*